Lyka Labs Ltd
LYKALABSLyka Labs Ltd
LYKALABSPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-124.86 | 9.40 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
53.11 | 5.97 | 0.54% |
Forecast & Ratings
Detailed ForecastPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Lyka Labs Limited is a pharmaceutical products and services provider. The Company is primarily engaged in formulation and manufacturing lyophilized products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 178.60 | 146.54 | 112.32 | 65.39 | 72.87 | 66.33 | 87.81 | 196.17 | 96.72 | 107.26 | ||||||||||
Raw Materials | 90.75 | 67.90 | 55.78 | 27.58 | 35.80 | 36.46 | 34.91 | 53.38 | 38.76 | 89.52 | ||||||||||
Power & Fuel Cost | 2.06 | 1.39 | 1.90 | 1.86 | 2.28 | 2.56 | 2.94 | 3.92 | 3.60 | |||||||||||
Employee Cost | 17.26 | 14.71 | 17.24 | 16.98 | 14.69 | 13.86 | 14.57 | 18.06 | 18.61 | |||||||||||
Selling & Administrative Expenses | 22.04 | 16.47 | 6.33 | 8.76 | 11.30 | 9.00 | 7.57 | 13.92 | 12.71 | |||||||||||
Operating & Other expenses | 14.88 | 17.65 | 10.20 | 9.39 | 9.75 | 38.24 | 7.71 | 10.17 | 10.19 | |||||||||||
EBITDA | 31.61 | 28.42 | 20.87 | 0.82 | -0.95 | -33.79 | 20.11 | 96.72 | 12.85 | 17.74 | ||||||||||
Depreciation/Amortization | 10.87 | 9.32 | 10.25 | 11.28 | 7.31 | 8.01 | 8.32 | 17.35 | 14.15 | 13.37 | ||||||||||
PBIT | 20.74 | 19.10 | 10.62 | -10.46 | -8.26 | -41.80 | 11.79 | 79.37 | -1.30 | 4.37 | ||||||||||
Interest & Other Items | 24.16 | 15.19 | 18.72 | 9.58 | 7.17 | 20.07 | 25.94 | 20.13 | 11.87 | 6.67 | ||||||||||
PBT | -3.42 | 3.91 | -8.10 | -20.04 | -15.43 | -61.87 | -14.15 | 59.24 | -13.17 | -2.30 | ||||||||||
Taxes & Other Items | 1.06 | 0.21 | -2.57 | -2.77 | -9.87 | -1.33 | -2.60 | 20.24 | 0.04 | 1.22 | ||||||||||
Net Income | -4.48 | 3.70 | -5.53 | -17.27 | -5.56 | -60.54 | -11.55 | 39.00 | -13.21 | -3.52 | ||||||||||
EPS | -2.08 | 1.70 | -2.51 | -6.88 | -1.98 | -21.31 | -4.03 | 13.59 | -4.45 | -1.15 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Lyka Labs Ltd | -33.27 | 9.40 | — |
Sun Pharmaceutical Industries Ltd | 42.66 | 6.09 | 0.76% |
Cipla Ltd | 40.61 | 4.80 | 0.60% |
Dr Reddy's Laboratories Ltd | 23.10 | 4.47 | 0.64% |
Price Comparison
Compare LYKALABS with any stock or ETFShareholdings
Promoter Holdings Trend
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Apr 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
LYKALABS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
News & Opinions
Lyka Labs Consolidated September 2023 Net Sales at Rs 27.99 crore, up 9.64% Y-o-Y
5 months ago•Moneycontrol
Lyka Labs Standalone June 2023 Net Sales at Rs 21.24 crore, down 2.93% Y-o-Y
8 months ago•Moneycontrol
Stocks that will see action on March 22, 2023
1 year ago•The Hindu Businessline
Kohinoor Foods Ltd leads losers in ‘B’ group
1 year ago•Business Standard
Lyka Labs shares jump 5% on signing pact to buy Agilis’ animal healthcare business
1 year ago•Business Today
IOL Chemicals & Pharma shares fall 4% on fag-end sell-off, pause 2-day winning run
1 year ago•Business Today
Biofil Chemicals & Pharmaceuticals Ltd leads gainers in ‘B’ group
1 year ago•Business Standard
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.14%, vs industry avg of 8.36%
Constant Market Share
Over the last 5 years, market share stayed at 0.03%